1. Market Research
  2. > Transplantation – Pipeline Review, H1 2013

Transplantation – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 203 pages

Transplantation – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Transplantation - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transplantation. Transplantation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Transplantation.
- A review of the Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Transplantation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Transplantation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Transplantation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Transplantation - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Transplantation Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Transplantation 10
Transplantation Therapeutics under Development by Companies 12
Transplantation Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
Transplantation Therapeutics - Products under Development by Companies 23
Transplantation Therapeutics - Products under Investigation by Universities/Institutes 28
Companies Involved in Transplantation Therapeutics Development 29
Kyowa Hakko Kirin Co., Ltd. 29
Athersys, Inc. 30
GlaxoSmithKline plc 31
AbGenomics International, Inc. 32
Emergent BioSolutions Inc. 33
Albany Molecular Research, Inc. 34
BioLineRx, Ltd. 35
Astellas Pharma Inc. 36
ViroPharma Incorporated 37
Genmab A/S 38
Exelixis, Inc. 39
Celldex Therapeutics, Inc. 40
Clinuvel Pharmaceuticals Limited 41
NeoStem, Inc. 42
Synta Pharmaceuticals Corp. 43
Cellerant Therapeutics, Inc. 44
University of Erlangen-Nurnberg 45
Digna Biotech, S.L. 46
Viron Therapeutics, Inc. 47
Wellstat Therapeutics Corporation 48
Argos Therapeutics, Inc. 49
ApoImmune, Inc. 50
Recoly N.V. 51
TetraLogic Pharmaceuticals 52
Fresenius Biotech GmbH 53
NovImmune SA 54
TcL Pharma SAS 55
Omeros Corporation 56
Trillium Therapeutics Inc. 57
iBio, Inc. 58
Kiadis Pharma B.V. 59
Bellicum Pharmaceuticals, Inc. 60
Sirnaomics, Inc. 61
USV Limited. 62
Limerick BioPharma, Inc. 63
KYORIN Pharmaceutical Co., Ltd. 64
Tolera Therapeutics, Inc. 65
Medistem, Inc. 66
Medestea Research and Production S.p.A. 67
TikoMed AB 68
Dompe Farmaceutici S.p.A. 69
AIMM Therapeutics B.V. 70
Amplimmune, Inc. 71
Bio Sidus S.A. 72
Neumedicines Inc. 73
CellAct Pharma GmbH 74
Immune Technologies and Medicine 75
Sigmoid Pharma. 76
Transplantation - Therapeutics Assessment 77
Assessment by Monotherapy Products 77
Assessment by Combination Products 78
Assessment by Route of Administration 79
Assessment by Molecule Type 81
Drug Profiles 84
ASKP-1240 - Drug Profile 84
MultiStem - Drug Profile 85
PN-951 - Drug Profile 87
CRACM Channel Inhibitors - Drug Profile 88
NI-0401 - Drug Profile 90
HuMax-TAC - Drug Profile 91
AMP-110 - Drug Profile 92
Reviroc - Drug Profile 94
VT-111a - Drug Profile 95
conestat alfa - Drug Profile 96
AGS-010 - Drug Profile 98
NecLip-G-CSF - Drug Profile 99
afamelanotide - Drug Profile 100
MD-707 - Drug Profile 101
Necrostatin Program - Drug Profile 102
MP-196 - Drug Profile 103
MF-280 - Drug Profile 104
FR-104 - Drug Profile 105
ApoFasL - Drug Profile 106
IBsolvMIR - Drug Profile 107
CTLA-4 X mono-IL-10 - Drug Profile 108
Cyclosporin Analogues - Drug Profile 109
IMP-731 - Drug Profile 110
KRP-107 - Drug Profile 112
KRP-203 - Drug Profile 113
OMS-721 - Drug Profile 115
CLT-008 - Drug Profile 117
LIM-0705 + [tacrolimus] - Drug Profile 118
CMV specific cytotoxic T lymphocytes - Drug Profile 119
Aptamer-Targeted Costimulatory Ligand Aptamer - Drug Profile 121
ATG-Fresenius S - Drug Profile 122
reparixin - Drug Profile 123
ApoCell - Drug Profile 125
sitagliptin phosphate - Drug Profile 126
MTP-131 - Drug Profile 127
methylthioadenosine - Drug Profile 129
alemtuzumab + [tacrolimus] - Drug Profile 131
NMIL12-1 - Drug Profile 132
CaspaCIDE ASC - Drug Profile 134
CD-200 Fusion Protein - Drug Profile 135
S1P1R Agonist - Drug Profile 136
STP-900 - Drug Profile 137
ASP-2408 - Drug Profile 138
Athelos T Cell Therapeutic - Drug Profile 139
PluraStem - Drug Profile 140
ES-301 - Drug Profile 141
Anti-CD-86 X Mono-IL-10 - Drug Profile 142
Rituximab Biosimilar - Drug Profile 143
LIM-0705 - Drug Profile 144
Tolerostem Program - Drug Profile 146
BL-8040 - Drug Profile 147
MorphoGel - Drug Profile 149
IL-1Ra - Drug Profile 150
ASP-2409 - Drug Profile 152
Human Monoclonal Antibodies Program For CMV - Drug Profile 153
CAP1.1 - Drug Profile 154
Notch Binding Proteins Program - Drug Profile 155
belatacept - Drug Profile 156
denileukin diftitox - Drug Profile 157
Bone Marrow Derived Mesenchymal Stem Cells - Drug Profile 158
semaphorin-6D - Drug Profile 159
Drug For Immune Supression - Drug Profile 160
Platelet Receptors Inhibitor - Drug Profile 161
tacrolimus Nanosomal - Drug Profile 162
CyLow - Drug Profile 163
MED-1101 - Drug Profile 164
Transplantation Therapeutics - Drug Profile Updates 165
Transplantation Therapeutics - Discontinued Products 187
Transplantation Therapeutics - Dormant Products 188
Transplantation - Product Development Milestones 191
Featured News and Press Releases 191
Appendix 197
Methodology 197
Coverage 197
Secondary Research 197
Primary Research 197
Expert Panel Validation 197
Contact Us 198
Disclaimer 198

List of Tables

Number of Products Under Development for Transplantation, H1 2013 15
Products under Development for Transplantation - Comparative Analysis, H1 2013 16
Number of Products under Development by Companies, H1 2013 18
Number of Products under Development by Companies, H1 2013 (Contd..1) 19
Number of Products under Development by Companies, H1 2013 (Contd..2) 20
Number of Products under Development by Companies, H1 2013 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H1 2013 23
Comparative Analysis by Late Stage Development, H1 2013 24
Comparative Analysis by Mid Clinical Stage Development, H1 2013 25
Comparative Analysis by Early Clinical Stage Development, H1 2013 26
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 27
Products under Development by Companies, H1 2013 28
Products under Development by Companies, H1 2013 (Contd..1) 29
Products under Development by Companies, H1 2013 (Contd..2) 30
Products under Development by Companies, H1 2013 (Contd..3) 31
Products under Development by Companies, H1 2013 (Contd..4) 32
Products under Investigation by Universities/Institutes, H1 2013 33
Kyowa Hakko Kirin Co., Ltd., H1 2013 34
Athersys, Inc., H1 2013 35
GlaxoSmithKline plc, H1 2013 36
AbGenomics International, Inc., H1 2013 37
Emergent BioSolutions Inc., H1 2013 38
Albany Molecular Research, Inc., H1 2013 39
BioLineRx, Ltd., H1 2013 40
Astellas Pharma Inc., H1 2013 41
ViroPharma Incorporated, H1 2013 42
Genmab A/S, H1 2013 43
Exelixis, Inc., H1 2013 44
Celldex Therapeutics, Inc., H1 2013 45
Clinuvel Pharmaceuticals Limited, H1 2013 46
NeoStem, Inc., H1 2013 47
Synta Pharmaceuticals Corp., H1 2013 48
Cellerant Therapeutics, Inc., H1 2013 49
University of Erlangen-Nurnberg, H1 2013 50
Digna Biotech, S.L., H1 2013 51
Viron Therapeutics, Inc., H1 2013 52
Wellstat Therapeutics Corporation, H1 2013 53
Argos Therapeutics, Inc., H1 2013 54
ApoImmune, Inc., H1 2013 55
Recoly N.V., H1 2013 56
TetraLogic Pharmaceuticals, H1 2013 57
Fresenius Biotech GmbH, H1 2013 58
NovImmune SA, H1 2013 59
TcL Pharma SAS, H1 2013 60
Omeros Corporation, H1 2013 61
Trillium Therapeutics Inc., H1 2013 62
iBio, Inc., H1 2013 63
Kiadis Pharma B.V., H1 2013 64
Bellicum Pharmaceuticals, Inc., H1 2013 65
Sirnaomics, Inc., H1 2013 66
USV Limited., H1 2013 67
Limerick BioPharma, Inc., H1 2013 68
KYORIN Pharmaceutical Co., Ltd., H1 2013 69
Tolera Therapeutics, Inc., H1 2013 70
Medistem, Inc., H1 2013 71
Medestea Research and Production S.p.A., H1 2013 72
TikoMed AB, H1 2013 73
Dompe Farmaceutici S.p.A., H1 2013 74
AIMM Therapeutics B.V., H1 2013 75
Amplimmune, Inc., H1 2013 76
Bio Sidus S.A., H1 2013 77
Neumedicines Inc., H1 2013 78
CellAct Pharma GmbH, H1 2013 79
Immune Technologies and Medicine, H1 2013 80
Sigmoid Pharma., H1 2013 81
Assessment by Monotherapy Products, H1 2013 82
Assessment by Combination Products, H1 2013 83
Assessment by Stage and Route of Administration, H1 2013 85
Assessment by Stage and Molecule Type, H1 2013 88
Transplantation Therapeutics - Drug Profile Updates 170
Transplantation Therapeutics - Discontinued Products 192
Transplantation Therapeutics - Dormant Products 193
Transplantation Therapeutics - Dormant Products (Contd..1) 194
Transplantation Therapeutics - Dormant Products (Contd..2) 195

List of Figures

Number of Products under Development for Transplantation, H1 2013 15
Products under Development for Transplantation - Comparative Analysis, H1 2013 16
Products under Development by Companies, H1 2013 17
Products under Investigation by Universities/Institutes, H1 2013 22
Late Stage Products, H1 2013 24
Mid Clinical Stage Products, H1 2013 25
Early Clinical Stage Products, H1 2013 26
Discovery and Pre-Clinical Stage Products, H1 2013 27
Assessment by Monotherapy Products, H1 2013 82
Assessment by Combination Products, H1 2013 83
Assessment by Route of Administration, H1 2013 84
Assessment by Stage and Route of Administration, H1 2013 85
Assessment by Molecule Type, H1 2013 86
Assessment by Stage and Molecule Type, H1 2013 87

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.